[go: up one dir, main page]

WO2008010061A3 - 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation - Google Patents

3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation Download PDF

Info

Publication number
WO2008010061A3
WO2008010061A3 PCT/IB2007/002002 IB2007002002W WO2008010061A3 WO 2008010061 A3 WO2008010061 A3 WO 2008010061A3 IB 2007002002 W IB2007002002 W IB 2007002002W WO 2008010061 A3 WO2008010061 A3 WO 2008010061A3
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
processes
hexane
receptor ligands
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002002
Other languages
English (en)
Other versions
WO2008010061A2 (fr
Inventor
Laxmikant Atmaram Gharat
Neelima Khairatkar Joshi
Jitendra Maganbhai Gajera
Pravin Sabhajit Yadav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of WO2008010061A2 publication Critical patent/WO2008010061A2/fr
Publication of WO2008010061A3 publication Critical patent/WO2008010061A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés substitués de 3-azabicyclo[3.1.0]hexane utilisables en tant que ligands du récepteur vanilloïde, ainsi que des procédés qui les utilisent pour traiter des maladies, des affections et/ou des troubles induits par les récepteurs vanilloïdes et des procédés permettant de les préparer.
PCT/IB2007/002002 2006-07-17 2007-07-16 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation Ceased WO2008010061A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IN1136MU2006 2006-07-17
IN1136/MUM/2006 2006-07-17
US83556006P 2006-08-03 2006-08-03
US60/835,560 2006-08-03
IN381/MUM/2007 2007-02-27
IN381MU2007 2007-02-27
US89367507P 2007-03-08 2007-03-08
US60/893,675 2007-03-08
US94771507P 2007-07-03 2007-07-03
US60/947,715 2007-07-03

Publications (2)

Publication Number Publication Date
WO2008010061A2 WO2008010061A2 (fr) 2008-01-24
WO2008010061A3 true WO2008010061A3 (fr) 2008-04-17

Family

ID=38928004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002002 Ceased WO2008010061A2 (fr) 2006-07-17 2007-07-16 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation

Country Status (2)

Country Link
AR (1) AR061905A1 (fr)
WO (1) WO2008010061A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2009034433A2 (fr) * 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. Dérivés de 3-azabicyclo [3.1.0] hexane utilisés comme ligands des récepteurs vanilloïdes
WO2009090548A2 (fr) * 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. Dérivés de 3-azabicyclo[3.1.0]hexane utilisés comme ligands des récepteurs vanilloïdes
CA2806634A1 (fr) * 2010-08-20 2012-02-23 Gruenenthal Gmbh Derives de carboxamide et d'uree cycliques substitues en tant que ligands du recepteur vanilloide
MX2016016202A (es) * 2014-06-12 2017-07-28 Allocyte Pharmaceuticals Ag Inhibidores de molecula pequeña de antigeno-1 asociado a funcion de linfocitos (lfa-1).
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
CA3142351A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
WO2021076886A1 (fr) 2019-10-18 2021-04-22 The Regents Of The University Of California Dérivés de 3-phénylsulfonyl-quinoléine en tant qu'agents pour le traitement de troubles des vaisseaux sanguins pathogènes
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018001A1 (fr) * 1992-03-02 1993-09-16 Pfizer Inc. Preparation d'intermediaires dans la synthese d'antibiotiques a la quinoline
US5475116A (en) * 1994-04-29 1995-12-12 Pfizer Inc. Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6194438B1 (en) * 1998-12-02 2001-02-27 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives
WO2002090326A1 (fr) * 2001-05-02 2002-11-14 Smithkline Beecham P.L.C. Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide
WO2004052857A1 (fr) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
WO2004078749A1 (fr) * 2003-03-06 2004-09-16 Glaxo Group Limited Derives d'uree heterocycliques pour le traitement de la douleur
WO2005051390A1 (fr) * 2003-10-29 2005-06-09 Merck Sharp & Dohme Limited Derives de 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide et composes associes modulant la fonction du recepteur vanilloide (vr1) pour le traitement de la douleur
WO2007029086A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derives de 3-azabicyclo[3.1.0]hexane en tant qu'inhibiteurs de la dipeptidyl peptidase-iv
WO2007077508A2 (fr) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Dérivés de bêta-aminoacides comme inhibiteurs de la dipeptidylpeptidase iv

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018001A1 (fr) * 1992-03-02 1993-09-16 Pfizer Inc. Preparation d'intermediaires dans la synthese d'antibiotiques a la quinoline
US5475116A (en) * 1994-04-29 1995-12-12 Pfizer Inc. Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
US6194438B1 (en) * 1998-12-02 2001-02-27 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one, and compositions and methods for inhibiting abnormal cell growth comprising said derivatives
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
WO2002090326A1 (fr) * 2001-05-02 2002-11-14 Smithkline Beecham P.L.C. Urees heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur vanilloide
WO2004052857A1 (fr) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
WO2004078749A1 (fr) * 2003-03-06 2004-09-16 Glaxo Group Limited Derives d'uree heterocycliques pour le traitement de la douleur
WO2005051390A1 (fr) * 2003-10-29 2005-06-09 Merck Sharp & Dohme Limited Derives de 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide et composes associes modulant la fonction du recepteur vanilloide (vr1) pour le traitement de la douleur
WO2007029086A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derives de 3-azabicyclo[3.1.0]hexane en tant qu'inhibiteurs de la dipeptidyl peptidase-iv
WO2007077508A2 (fr) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Dérivés de bêta-aminoacides comme inhibiteurs de la dipeptidylpeptidase iv

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEM. EUROP. J., vol. 8, no. 16, 2002, pages 3789 - 3801 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002465472, Database accession no. BRN:8563110 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002465473, Database accession no. BRN:9222926 *
ELMAR VILSMAIER ET AL: "Reductive decyanation of N-protected 6-Amino-3-azabicyclo(3.1.0)hexan ecarbonitriles", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 54, no. 23, 1998, pages 6403 - 6414, XP002081309, ISSN: 0040-4020 *
GILLASPY M L ET AL: "A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 36, no. 41, 9 October 1995 (1995-10-09), pages 7399 - 7402, XP004027008, ISSN: 0040-4039 *
J. CHEM. SOC. PERKIN TRANS., vol. 10, 2000, pages 1615 - 1622 *

Also Published As

Publication number Publication date
WO2008010061A2 (fr) 2008-01-24
AR061905A1 (es) 2008-10-01

Similar Documents

Publication Publication Date Title
WO2008010061A3 (fr) 3-azabicyclo[3.1.0]hexanes ligands du récepteur vanilloïde, compositions pharmaceutiques les contenant et leurs procédés de préparation
WO2009090548A3 (fr) Dérivés de 3-azabicyclo[3.1.0]hexane utilisés comme ligands des récepteurs vanilloïdes
WO2010109334A3 (fr) Dérivés de thiénopyrimidinedione comme modulateurs de trpa1
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
PH12013501290A1 (en) 2-amino-4-arylthiazole compounds as trpa1 antagonists
WO2010048332A3 (fr) Composés de traitement de maladies et troubles ophtalmiques
WO2009118596A3 (fr) Dérivés de phtalimide en tant que modulateurs de trpa1
WO2009111700A3 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2008062276A8 (fr) Dérivés d'acétylène comme inhibiteurs de la stéaroyl coa désaturase
WO2012009009A3 (fr) Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
WO2008152093A3 (fr) Diaminopyrimidines en tant que modulateurs du récepteur ep2
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
WO2008059339A3 (fr) Dérivés d'isoquinoline comme modulateurs des récepteurs vanilloïdes
WO2008005908A3 (fr) Dérivés de pyridoïmidazole
WO2008153937A3 (fr) Nouveaux 1- hétéroaryl-3-azabicyclo[3.1.0]hexanes, leurs méthodes de préparation et leur utilisation comme médicaments
WO2011132051A3 (fr) Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
WO2010054024A3 (fr) Nouveaux composés en tant que ligands des récepteurs cannabinoïdes
WO2007052023A3 (fr) Composes
WO2010010435A3 (fr) Dérivés oxazole et thiazole fusionnés en tant que modulateurs de trpm8
WO2010007482A3 (fr) Dérivés de thiazole en tant qu’inhibiteurs de stéaroyl-coa désaturase
WO2009037542A3 (fr) Composés spirocycliques en tant qu'inhibiteurs de stéaroyle coa désaturase
WO2009084034A3 (fr) Dérivés de chromane utilisés comme modulateurs de trpv3
WO2007079163A3 (fr) Antagonistes du recepteur de la prokineticine 1
WO2009038385A3 (fr) Nouveaux composés présentant des squelettes d'indazole, méthodes de préparation de ceux-ci et composition pharmaceutique les contenant
WO2007150010A3 (fr) Dérivés de cyclopropylamines

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804611

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07804611

Country of ref document: EP

Kind code of ref document: A2